연구동향 분석

ORIGINAL ARTICLE : The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea

( Cheolsu Kim ) ( Ho Sup Lee ) ( Chang Ki Min ) ( Je Jung Lee ) ( Ki Hyun Kim ) Dok Hyun Yoon ( Hyeon Seok Eom ) ( Hye Won Lee ) ( Won Sik Lee ) Ho Jin Shin ( Ji Hyun Lee ) ( Yong Park ) ( Jae Cheol Jo ) ( Young Rok Do ) 2015년

논문상세정보
인용/피인용
' ORIGINAL ARTICLE : The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • inflammation
  • multiple myeloma
  • prognosis
  • thalidomide
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
1,046 0

0.0%

' ORIGINAL ARTICLE : The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea' 의 참고문헌

  • Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma
    Lokhorst HM Haematologica 93 : 124 ~ 127 [2008]
  • Thalidomide for treatment of multiple myeloma: 10 years later
    Palumbo A Blood 111 : 3968 ~ 3977 [2008]
  • Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma
    Kyrtsonis MC Semin Hematol 46 : 110 ~ 117 [2009]
  • Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity
    Papadaki H Acta Haematol 97 : 191 ~ 195 [1997]
  • Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias
    Bataille R J Clin Invest 84 : 2008 ~ 2011 [1989]
  • Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma
    Kim JE Ann Hematol 89 : 391 ~ 397 [2010]
  • Role of thalidomide in the treatment of patients with multiple myeloma
    Morgan GJ Crit Rev Oncol Hematol 88 (Suppl 1) : S14 ~ S22 [2013]
  • Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma
    Kyrtsonis MC Br J Haematol 137 : 240 ~ 243 [2007]
  • Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival
    Barlogie B Ann Hematol 90 : 423 ~ 428 [2011]
  • Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study
    Ege H Br J Haematol 141 : 792 ~ 798 [2008]
  • Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management
    Rajkumar SV. Am J Hematol 88 : 226 ~ 235 [2013]
  • Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013
    Mikhael JR Mayo Clin Proc 88 : 360 ~ 376 [2013]
  • Lactate dehydrogenase and its isoenzymes in serum from patients with multiple myeloma
    Copur S Clin Chem 35 : 1968 ~ 1970 [1989]
  • International staging system for multiple myeloma
    Greipp PR J Clin Oncol 23 : 3412 ~ 3420 [2005]
  • International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation
    Palumbo A J Clin Oncol 32 : 587 ~ 600 [2014]
  • International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation
    Cavo M Blood 117 : 6063 ~ 6073 [2011]
  • Initial treatment of transplant candidates with multiple myeloma
    Moreau P Semin Oncol 40 : 585 ~ 591 [2013]
  • Ferritin as prognostic marker in multiple myeloma patients undergoing autologous transplantation
    Strasser-Weippl K Leuk Lymphoma 55 : 2520 ~ 2524 [2014]
  • European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
    Engelhardt M Haematologica 99 : 232 ~ 242 [2014]
  • Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study
    Ahn SY Ann Hematol 93 : 1571 ~ 1577 [2014]
  • Cytogenetic classification in Korean multiple myeloma patients: prognostic significance of hyperdiploidy with 47-50 chromosomes and the number of structural abnormalities
    Lim JH Eur J Haematol 92 : 313 ~ 320 [2014]
  • Continuous treatment in multiple myeloma: the future?
    Vande Broek I Transfus Apher Sci 49 : 147 ~ 150 [2013]
  • Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study
    Oh S Ann Hematol 93 : 1353 ~ 1361 [2014]
  • C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system
    Bataille R Blood 80 : 733 ~ 737 [1992]
  • Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stemcell transplantation in newly diagnosed multiple myeloma:a randomised phase 3 study
    Cavo M Lancet 376 : 2075 ~ 2085 [2010]
  • Autologous stem cell transplantation in elderly patients with multiple myeloma: past, present, and future
    Ozaki S Biomed Res Int 2014 : 394792 ~ [2014]
  • A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications
    Lauta VM. Cancer 97 : 2440 ~ 2452 [2003]
  • A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival
    Durie BG Cancer 36 : 842 ~ 854 [1975]
  • 10 Years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group
    Minarik J Leuk Res 37 : 1063 ~ 1069 [2013]